| Hydroquinone for skin lightening: safety profile, duration of use and when should we stop? | |
| | |
MedLine Citation:
|
PMID: 20095963 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Hydroquinone has been marketed in skin-lightening products for almost 50 years and remains as the most frequently used whitening constituent in the category. Issues and concerns have been raised regarding its potential dermatological and systemic side effects. These almost led to it being banned from the US market by the FDA in 2006. This article reviews its safety profile. The author also suggests on the duration of its use and advises on regular assessments by medical physicians. |
| | |
Authors:
|
Tsz Wah Tse |
Related Documents
:
|
16931103 - Characteristics of drug misusers in custody and their perceptions of medical care. 11013543 - The enduring and evolving nature of the patient-physician relationship. 9134493 - Kindness, prescribed and natural, in medicine. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: The Journal of dermatological treatment Volume: 21 ISSN: 1471-1753 ISO Abbreviation: J Dermatolog Treat Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-08-06 Completed Date: 2010-12-17 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8918133 Medline TA: J Dermatolog Treat Country: England |
Other Details:
|
Languages: eng Pagination: 272-5 Citation Subset: IM |
Affiliation:
|
Private Practice, 14/F, Manning House, 48 Queen's Road, Central, Hong Kong. tsz910@hotmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Consumer Product Safety Dermatologic Agents / administration & dosage*, adverse effects* Humans Hydroquinones / administration & dosage*, adverse effects* Melanocytes / drug effects Pigmentation Disorders / drug therapy* Skin Pigmentation / drug effects* Time Factors Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Dermatologic Agents; 0/Hydroquinones; 123-31-9/hydroquinone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Renal UDP-glucuronosyltransferases and the glucuronidation of xenobiotics and endogenous mediators.
Next Document: S165F mutation of junctophilin-2 affects Ca2+ signaling in skeletal muscle.